When was Evozyne founded?

Evozyne was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Evozyne located?

Evozyne is headquartered in Chicago, United States.

How many employees does Evozyne have?

As of Apr 30, 2026, the latest employee count at Evozyne is 54.

Is Evozyne a funded company?

Evozyne is a funded company, having raised a total of $144M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 27, 2020.

When was the latest funding round of Evozyne?

Evozyne's latest funding was a $***** Series B round on Sep 14, 2023, with participation from 5 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.55B in funding in 2026 to date.

Where does Evozyne rank among its competitors?

Evozyne ranks 16th amongst 77 active competitors, of which 41 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Profluent Bio, which secured $106M in Nov, 2025.

Who are the top competitors of Evozyne?

Evozyne's top competitors include Nimbus Therapeutics, Generate Biomedicines and Frontier Medicines. Among them, Profluent Bio secured the most recent funding round in November, 2025.

Evozyne - 2026 Company Profile, Team, Funding & Competitors

Evozyne is a series B company based in Chicago (United States), founded in 2020 by Rama Ranganathan. It operates as a Developer of proteins using protein engineering technology. Evozyne has raised $144M in funding from Fidelity Investments and Orbimed. The company has 77 active competitors, including 41 funded and 5 that have exited. Its top competitors include companies like Nimbus Therapeutics, Generate Biomedicines and Frontier Medicines.

Company Details

Evozyne has developed novel proteins using protein engineering technology. The company uses machine learning, statistical techniques with high throughput gene synthesis and screening technology to build predictive models of sequence-function relationships for a family of proteins for synthesis, and characterizing of the proteins.

Key Metrics

Founded Year

2020

Location

Chicago, United States

Stage

Series B

Total Funding

$144M in 4 rounds

Latest Funding Round

Series B, Sep 14, 2023, $*****

Investors

Fidelity Investments & 4 more

Ranked

16^th among 77 active competitors

Employee Count

54 as on Apr 30, 2026

Similar Companies

Nimbus Therapeutics & 81 more

View Evozyne's full profile

Evozyne has raised a total funding of $144M over 4 rounds. Its first funding round was on Apr 27, 2020. Its latest funding round was a Series B round on Sep 14, 2023 for $*****. 5 investors participated in its latest round. Evozyne has 5 institutional investors.

Here is the list of recent funding rounds of Evozyne:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 14, 2023	1869479	Series B	1721718	2491249	1778608	1028987
Sep 14, 2023	4990225	Conventional Debt	2593040	2358302	8378156	2655954
Apr 09, 2021	8947423	Series B	2522645	4255163	2191025	1072744

Access funding benchmarks and valuations. Sign up today!

View details of Evozyne's funding rounds and investors

The founders of Evozyne is Rama Ranganathan.

Here are the details of Evozyne's key team members:

Rama Ranganathan: Co-Founder & CSO of Evozyne.

View details of Evozyne's Founder profiles and Board Members

Evozyne's employee count trend

Evozyne has 54 employees as of Apr 26. Here is Evozyne's employee count trend over the years:

Uncover Evozyne's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evozyne include Nimbus Therapeutics, Generate Biomedicines and Frontier Medicines. Here is the list of Top 10 competitors of Evozyne, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	NVentures, Pictet Group & 14 others	66/100
3rd	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	64/100
4th	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Insight Partners, Bezos Expeditions & 6 others	64/100
5th	Cradle 2021, Delft (Netherlands), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, IVP & 7 others	64/100
6th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, ADIA & 22 others	62/100
7th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	61/100
8th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Versant Ventures, Arch Venture Partners & 21 others	61/100
9th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, University of Oxford ... & 11 others	59/100
10th	Nomic 2017, Montreal (Canada), Series B	Provider of next-generation proteomics platform for drug discovery and protein analysis	$63M	Lux Capital, Amplitude & 13 others	56/100
16th	Evozyne 2020, Chicago (United States), Series B	Developer of proteins using protein engineering technology	$144M	Fidelity Investments, Valor Equity Partners ... & 3 others	49/100